Home > > North America And Global Osteoarthritis Therapeutics Market- Size, Share, Growth Rate, and Forecast
The North America Osteoarthritis Therapeutics market was valued at $2,913.8 Million in 2023, and is projected to reach $5,388.7 Million by 2030 growing at a CAGR of 9.23% from 2024 to 2030. Knee osteoarthritis segment is expected to be the highest contributor to this market, with $2,203.6 Million in 2023, and is anticipated to reach $4,144.9 by 2030, registering a CAGR of 9.50%. Small joint osteoarthritis segment is anticipated to reach $380.7 Million by 2030 with the highest CAGR of 10.90%. Knee osteoarthritis and Hip osteoarthritis segments collectively expected to account for about 87.1% share of the North America Osteoarthritis Therapeutics market in 2023, with the former constituting around 75.6% share. Small joint osteoarthritis and Knee osteoarthritis segments are expected to witness significant growth rates at a CAGR of 10.90% and 9.50% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 82.0% in the overall North America Osteoarthritis Therapeutics market in 2023, and is anticipated to reach 84.0% by 2030. Anatomy Knee osteoarthritis Hip osteoarthritis Hand osteoarthritis Small joint osteoarthritis Drug Type Viscosupplementation agents Nonsteroidal anti-inflammatory drugs Analgesics Corticosteroids Route of Administration Parenteral route Oral route Topical route BY REGION North America US Canada Europe Germany UK France Italy Spain RoE Asia Japan China India Australia RoAPAC Middle East & Africa Latin America MEA